AARDVARK THERAPEUTICS INC (AARD) Stock Fundamental Analysis

NASDAQ:AARD • US0029421007

12.32 USD
-0.09 (-0.73%)
At close: Feb 20, 2026
12.3035 USD
-0.02 (-0.13%)
After Hours: 2/20/2026, 8:15:33 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

AARD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. AARD has a great financial health rating, but its profitability evaluates not so good. AARD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year AARD has reported negative net income.
  • In the past year AARD has reported a negative cash flow from operations.
AARD Yearly Net Income VS EBIT VS OCF VS FCFAARD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • AARD's Return On Assets of -36.61% is in line compared to the rest of the industry. AARD outperforms 45.31% of its industry peers.
  • AARD's Return On Equity of -39.85% is in line compared to the rest of the industry. AARD outperforms 57.81% of its industry peers.
Industry RankSector Rank
ROA -36.61%
ROE -39.85%
ROIC N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AARD Yearly ROA, ROE, ROICAARD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AARD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AARD Yearly Profit, Operating, Gross MarginsAARD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • The number of shares outstanding for AARD remains at a similar level compared to 1 year ago.
  • There is no outstanding debt for AARD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AARD Yearly Shares OutstandingAARD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
AARD Yearly Total Debt VS Total AssetsAARD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • AARD has an Altman-Z score of 13.54. This indicates that AARD is financially healthy and has little risk of bankruptcy at the moment.
  • AARD has a better Altman-Z score (13.54) than 84.90% of its industry peers.
  • AARD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.54
ROIC/WACCN/A
WACCN/A
AARD Yearly LT Debt VS Equity VS FCFAARD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 12.03 indicates that AARD has no problem at all paying its short term obligations.
  • AARD's Current ratio of 12.03 is amongst the best of the industry. AARD outperforms 80.73% of its industry peers.
  • A Quick Ratio of 12.03 indicates that AARD has no problem at all paying its short term obligations.
  • The Quick ratio of AARD (12.03) is better than 80.73% of its industry peers.
Industry RankSector Rank
Current Ratio 12.03
Quick Ratio 12.03
AARD Yearly Current Assets VS Current LiabilitesAARD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • AARD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -185.61%.
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-284.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.54% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-211.47%
EPS Next 2Y-95.31%
EPS Next 3Y-60.96%
EPS Next 5Y22.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AARD Yearly Revenue VS EstimatesAARD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
AARD Yearly EPS VS EstimatesAARD Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • AARD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AARD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AARD Price Earnings VS Forward Price EarningsAARD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AARD Per share dataAARD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A cheap valuation may be justified as AARD's earnings are expected to decrease with -60.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-95.31%
EPS Next 3Y-60.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AARD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AARDVARK THERAPEUTICS INC

NASDAQ:AARD (2/20/2026, 8:15:33 PM)

After market: 12.3035 -0.02 (-0.13%)

12.32

-0.09 (-0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners53.17%
Inst Owner Change3.42%
Ins Owners14.55%
Ins Owner Change3.95%
Market Cap268.21M
Revenue(TTM)N/A
Net Income(TTM)-48.77M
Analysts87.78
Price Target33.29 (170.21%)
Short Float %9.54%
Short Ratio8.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.04%
Min EPS beat(2)-7.84%
Max EPS beat(2)7.92%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.19%
PT rev (3m)6.57%
EPS NQ rev (1m)0.3%
EPS NQ rev (3m)-0.83%
EPS NY rev (1m)0%
EPS NY rev (3m)0.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.19
P/tB 2.19
EV/EBITDA N/A
EPS(TTM)-2.53
EYN/A
EPS(NY)-3.67
Fwd EYN/A
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-2.07
OCFYN/A
SpS0
BVpS5.62
TBVpS5.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.61%
ROE -39.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 297.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.03
Quick Ratio 12.03
Altman-Z 13.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-284.15%
EPS Next Y-211.47%
EPS Next 2Y-95.31%
EPS Next 3Y-60.96%
EPS Next 5Y22.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-207.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-170.03%
EBIT Next 3Y-73.6%
EBIT Next 5YN/A
FCF growth 1Y-212.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.56%
OCF growth 3YN/A
OCF growth 5YN/A

AARDVARK THERAPEUTICS INC / AARD FAQ

What is the fundamental rating for AARD stock?

ChartMill assigns a fundamental rating of 3 / 10 to AARD.


Can you provide the valuation status for AARDVARK THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to AARDVARK THERAPEUTICS INC (AARD). This can be considered as Overvalued.


What is the profitability of AARD stock?

AARDVARK THERAPEUTICS INC (AARD) has a profitability rating of 1 / 10.


Can you provide the financial health for AARD stock?

The financial health rating of AARDVARK THERAPEUTICS INC (AARD) is 9 / 10.